BT 001
BioInvent’s oncolytic virus showcased at ESMO
At the 2025 ESMO Congress, BioInvent International and Transgene presented new and encouraging clinical data for the oncolytic virus candidate BT-001....
BioInvent's CMO comments on the presentation at ESMO
BioInvent and Transgene presented promising Phase I/IIa data for...
BioInvent makes a strong entrance at ESMO in Barcelona
BioInvent has published further positive preliminary efficacy data from...
BioInvent expects a continued news-rich 2024
With a cash position of over one billion SEK...
BioInvent comments on progress in breast cancer study
BioInvent's pipeline consists of five drug candidates that are advancing...
BioInvent is charging for presentations of clinical data
BioInvent reached a milestone in the third quarter...
BioInvent reaches research milestone in collaboration with Exelixis
BioInvent has reached a research milestone in its collaboration...
BioInvent will soon have five drug candidates in six clinical studies
BioInvent has made a number of advances during the...
BioInvent ready for combination studies with BT-001
BioInvent and its partner Transgene have reported positive results...
BioInvent's CFO on the company's business strategy
With a reported cash flow of just over 1,5 billion...
BioInvent reports clinical progress with BI-1206
A fourth complete response has been observed in phase...
BioInvent's CEO expects an eventful 2023
In 2022, the biotechnology company BioInvent demonstrated...